Key facts
- South Africa's antitrust watchdog may charge Adcock Ingram with profiteering.
- The accusations relate to the Covid-19 pandemic and alleged failure to pass on dialysis discounts.
- Adcock Ingram may face antitrust charges.
The Competition Commission of South Africa is investigating potential anti-competitive practices by pharmaceutical companies during the COVID-19 pandemic. This case highlights concerns about price gouging and profiteering during public health crises, specifically focusing on whether discounts were passed on to consumers.